Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Head of Fin. Quality Assurance | April 23, 2026 | April 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 188,671 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Sale · Disposed 1,641 · Balance 188,671 F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2038 to $5.2051, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2038 to $5.2051, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2026 Filed Apr 27, 2026 20:27 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 1,641 | $5.20 | $8,539.76 |
DisclosureSEC source: 0000905148-26-001865 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · Head of Fin. Quality Assurance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,671 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2038 to $5.2051, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 2,816 | $5.25 | $14,769.92 |
DisclosureSEC source: 0000905148-26-001382 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · Head of Fin. Quality Assurance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,312 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 22, 2026 Filed Jan 27, 2026 00:49 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 86,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000357 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · Head of Fin. Quality Assurance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,128 F1 · shares: Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service. Read SEC document |
| January 18, 2026 Filed Jan 21, 2026 21:05 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 3,390 | $2.10 | $7,119.00 |
DisclosureSEC source: 0000905148-26-000282 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · Head of Fin. Quality Assurance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,628 F1 · kind: The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. Not an open market sale of securities. Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 22:21 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 3,950 | $1.93 | $7,623.50 |
DisclosureSEC source: 0000905148-26-000164 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · Head of Fin. Quality Assurance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,018 F1 · kind: The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. Not an open market sale of securities. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:54 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 39,500 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000905148-25-000941 · form4.xml · derivative · entry 2 Zaremba Rabourn Amy · CIK 0001832343 · SVP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,500 Underlying: Common Stock · 39,500 shares Expires 2035-03-12 F2 · derivative.exercise_date: The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:54 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 39,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000941 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · SVP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,968 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:37 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 8,190 | $1.14 | $9,336.60 |
DisclosureSEC source: 0000905148-25-000403 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · SVP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,468 Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 23:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001140361-24-003191 · form4.xml · derivative · entry 2 Zaremba Rabourn Amy · CIK 0001832343 · SVP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-01-17 F2 · derivative.exercise_date: The option will vest with respect to 15,000 shares on January 18, 2025, with the balance vesting quarterly in twelve equal installments thereafter at the end of each quarter. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 23:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-003191 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · SVP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,658 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 18, 2024. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 21:17 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | Tax withholdingCommon Stock | 3,950 | $3.27 | $12,896.75 |
DisclosureSEC source: 0001140361-24-002128 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · SVP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,658 Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 22:30 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 69,912 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001140361-23-001508 · form4.xml · derivative · entry 2 Zaremba Rabourn Amy · CIK 0001832343 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,912 Underlying: Common Stock · 69,912 shares Expires 2033-01-09 F2 · derivative.exercise_date: The option will vest with respect to 17,478 shares on January 10, 2024, with the balance vesting quarterly in twelve equal installments thereafter. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 22:30 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 46,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-001508 · form4.xml · nonDerivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,608 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 10, 2023. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:23 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001140361-22-003492 · form4.xml · derivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: The option will vest with respect to 12,500 shares on January 28, 2023, and then with respect to 1,041 shares on the last day of each month from February 2023 through December 2025 and with respect to 1,065 shares at the end of January 2026. Read SEC document |
| November 11, 2020 Filed Nov 16, 2020 23:31 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001140361-20-025729 · form4.xml · derivative · entry 1 Zaremba Rabourn Amy · CIK 0001832343 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-11-11 F1 · derivative.exercise_date: 1,562 shares vest each month-end from November 2020 through October 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.